Patent ID: 8394796
Filing Date: 2013-03-12
Classification: A61P,C07D

Abstract:
1. A method of treating an immune-inflammatory disease mediated by the p110 delta isoform of PI3 kinase which method comprises administering a compound to a patient with an immune-inflammatory disease mediated by the p110 delta isoform of PI13 kinase, wherein the compound is selected from Formulas Ia and Ib: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein (i) X R C C C C —(C —(C —(C —(C —(C —(C —(C —(C —(C —(C —(C —(C —(C —(C —(C —(C —(C —(C —(C —(C —(C —(C —(C —(C —(C —(C —C(═O)—(C —C(═O)—(C —C(═O)—(C —C(═O)—(C —C(═O)—(C —C(═O)—NR —CR where alkyl, alkenyl, alkynyl, alkylene, carbocyclyl, heterocyclyl, aryl, and heteroaryl are optionally substituted with one or more groups independently selected from F, Cl, Br, I, —CH R R where R R n is 0, 1, 2, 3, or 4; R mor is a morpholine group or a bicyclic structure selected from: optionally substituted with one or more groups selected from F, Cl, Br, I, —CH and wherein the IC50 binding activity to p110 delta is ten or more times lower than the binding activity to p110 alpha.